BioVaxys Technology Corp Chief Medical Officer David Berd joined Proactive to discuss results from its in vivo animal research study support the safety and tolerability of CoviDTH at two intradermal dose levels across a battery of clinical pathology, immunology, and histopathology evaluations.
CoviDTH is the world's first and only low-cost, disposable, point-of-care diagnostic tool that screens for a T-cell response to SARS-CoV-2, the virus that causes coronavirus, according to BioVaxys.